JAK3
ENSG00000105639
Target class
Kinase
Chromosome
19
Approved drugs
8
Clinical candidates (approved and in development)
19
- Approved drugs
- 8
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 19
- Chemical probe available
- Yes
- Target name
- JAK3
- Gene name
- Janus kinase 3
- Gene symbol
- JAK3
- Protein name
- Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK)
- L-JAK
- JAKL
- LJAK
- JAK3_HUMAN
- JAK-3
- Gene biotype
- Protein coding
- Gene family
- Jak family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 139.15
- Tissue specificity (Gini)
- 0.64
- Tissue specificity (tau)
- 0.937
- KEGG gene identifiers
- hsa:3718
- Protein interaction confidence
- 0.84339
- Protein interaction partners
- 118
- R-HSA-1266695
- R-HSA-201556
- R-HSA-5673001
- R-HSA-6785807
- R-HSA-8854691
- R-HSA-8983432
- R-HSA-8985947
- R-HSA-9020558
- R-HSA-9020958
- R-HSA-912526
- R-HSA-9679191
- End position
- 17848071
- Start position
- 17824780
- Chromosome
- 19
- Strand
- Reverse
- Endomembrane system
- Peripheral membrane protein . Cytoplasm .
- Cytosol
- Plasma membrane
- Tissue specificity (tau)
- 0.936924
- Expression inequality (Gini)
- 0.640065
Expression in transcripts per million
- Whole Blood
- 139.15
- Spleen
- 108.55
- Cells - EBV-transformed lymphocytes
- 41.99
- Ovary
- 39.16
- Lung
- 27.5
Expression in transcripts per million
- Whole Blood139.15
- Spleen108.55
- Cells - EBV-transformed lymphocytes41.99
- Ovary39.16
- Lung27.5
- Small Intestine - Terminal Ileum16.01
- Fallopian Tube13.01
- Cervix - Endocervix11.18
- Adipose - Visceral (Omentum)10.88
- Thyroid9.54
- Prostate8.95
- Breast - Mammary Tissue7.99
- Kidney - Medulla7.83
- Adipose - Subcutaneous7.41
- Artery - Coronary7.15
- Testis6.77
- Bladder6.69
- Brain - Cerebellum6.4
- Nerve - Tibial6.19
- Minor Salivary Gland6.17
- Pituitary6.07
- Vagina5.95
- Brain - Cerebellar Hemisphere5.9
- Colon - Transverse5.36
- Brain - Hypothalamus5.32
And 29 more, listed on the interactive page.
- GO:0007260
- GO:0035723
- GO:0035771
- GO:0038110
- GO:0038111
- GO:0038113
- GO:0043029
- GO:0046425
- GO:0060397
- GO:0070669
- GO:0070670
- GO:0070672
- GO:0071104
- GO:2000329
- GO:0005768
- GO:0005829
- GO:0005886
- GO:0009898
- GO:0019897
- GO:0031234
- GO:0004713
- GO:0005515
- GO:0019903
Related records
Trials (508)
- 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
- 3T Therapy in the Treatment of MDA5-positive Dermatomyositis
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
- A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
- A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
- A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
- A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
- A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
- A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis
- A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS
- A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
- A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
- A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Drugs (22)
- AT-9283 Tyrosine-protein kinase JAK3 inhibitor
- Cerdulatinib Tyrosine-protein kinase JAK3 inhibitor
- Decernotinib Tyrosine-protein kinase JAK3 inhibitor
- Delgocitinib Janus Kinase (JAK) inhibitor
- Deuruxolitinib phosphate Tyrosine-protein kinase JAK3 inhibitor
- Filgotinib Tyrosine-protein kinase JAK3 inhibitor
- Filgotinib maleate Tyrosine-protein kinase JAK3 inhibitor
- Gusacitinib Janus Kinase (JAK) inhibitor
- Izencitinib Janus Kinase (JAK) inhibitor
- Nezulcitinib Janus Kinase (JAK) inhibitor
- Peficitinib Janus Kinase (JAK) inhibitor
- R-333 Tyrosine-protein kinase JAK3 inhibitor
- R-348 Tyrosine-protein kinase JAK3 inhibitor
- Ritlecitinib Tyrosine-protein kinase JAK3 inhibitor
- Ritlecitinib tosylate Tyrosine-protein kinase JAK3 inhibitor
- Ruxolitinib Tyrosine-protein kinase JAK3 inhibitor
- Tofacitinib Janus Kinase (JAK) inhibitor
- Tofacitinib citrate Janus Kinase (JAK) inhibitor
- Tricetamide Tyrosine-protein kinase JAK3 inhibitor
- Upadacitinib Tyrosine-protein kinase JAK3 inhibitor